Business Wire

PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics

Share

PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/

Follow Project-Comfort LinkedIn Page: https://www.linkedin.com/company/project-comfort (Graphic: Business Wire)

“We are proud to collaborate on this groundbreaking project, which perfectly aligns with our commitment to advancing healthcare solutions that prioritize patients,” said Luca Zanotti Fragonara, Advanced Technologies Competence Center Lead at PQE Group. “Together with our partners, we aim to make blood collection and diagnostics more accessible, comfortable, and efficient, ultimately improving health outcomes globally.”

On behalf of the consortium, Project Leader Antoniu L. Fantana, PhD, Sr. Director, Eli Lilly and Company stated: “Our goal is to redefine diagnostics by placing patient needs at the forefront and expanding healthcare access globally. Together with 51 dedicated organizations, we are committed to establishing a new standard in blood collection and diagnostics that combines patient comfort and accessibility with higher quality data.”

Traditional blood collection methods, such as venipuncture, can be burdensome and uncomfortable, particularly for patients with limited mobility, children, the elderly, and those in rural or underserved areas. The need to visit a clinical setting often poses additional challenges, including time, cost, and travel barriers. Project-COMFORT addresses these obstacles head-on by advancing Patient-Centric Microsampling — an approach allowing smaller blood samples to be collected comfortably at home or in other convenient locations. This shift will greatly enhance diagnostic accessibility, reduce patient discomfort, and make timely health monitoring a reality for those who need it most.

“By offering a minimally invasive, patient-friendly alternative, microsampling represents a major step forward in democratizing healthcare access,” noted Scientific Coordinator Chi Pakarinen. “Our project is about breaking down barriers to care and reimagining blood diagnostics as an inclusive, adaptable service that meets patients where they are.”

Project-COMFORT leverages the diverse expertise of its partners, blending insights from healthcare providers, research institutions, patient advocacy groups, and technology innovators. The aim is to also involve regulatory and HTA experts from the start to ensure the best chances for successful project implementation and better uptake of project results. This unique collaboration integrates advanced clinical research, regulatory compliance, and technological development, creating a robust foundation for microsampling to emerge as a recognized standard. With expertise spanning a broad array of disciplines, the consortium partners are collectively building a model that can lead to more patient-centered, efficient healthcare in the future.

“At the heart of Project-COMFORT is a commitment to patient-centered innovation,” said Administrative Coordinator Professor Georgios Theodoridis, School of Chemistry, Aristotle University of Thessaloniki. “This project holds groundbreaking potential to make Patient-Centric Microsampling an accepted alternative to traditional blood draws, fundamentally transforming the diagnostic experience for patients. By reducing the burden of testing and enhancing accessibility, we are paving the way for data-driven healthcare advancements that will improve patient outcomes and support more effective healthcare planning worldwide.”

The project’s ultimate goal is to generate impactful, data-driven insights that not only improve individual patient care but also guide public health strategies. The rich data made available through microsampling technology has the potential to influence healthcare policy, resource allocation, and preventive care measures, leading to a healthier, more resilient population.

With this launch, Project-COMFORT embarks on a journey of global impact, backed by €6,6 million in funding and an unparalleled commitment from its diverse network of partners. By engaging patient communities, healthcare providers, and regulatory bodies from the outset, the project will ensure that each stage of development is attuned to real-world needs and expectations. As Project-COMFORT progresses, regular updates and collaboration opportunities will be shared to welcome stakeholders into this groundbreaking healthcare transformation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241229266268/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 20:00:00 CET | Press release

Product combines fish-skin grafts and silicone for soft-tissue repair Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-st

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 12:00:00 CET | Press release

New indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancersSecond FDA approval for TEVIMBRA in 2024 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 07:00:00 CET | Press release

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and HypogammaglobulinemiaAdministration of Recombinant Human Hyaluronidase Prior toImmunoglobulin Facilitates Subcutaneous Infusion of Larger Volumes, Potentially Reducing Frequency and Giving Patients More FlexibilityApproval Expands Takeda’s Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company’s Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by pr

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye